Who makes EBV-specific T cells: B?

EBV-specific T cells: B is developed by Baylor College of Medicine.

What development phase is EBV-specific T cells: B in?

EBV-specific T cells: B is in Phase 1.

Last reviewed 2026-04-19 · How we verify

EBV-specific T cells: B

Baylor College of Medicine · Phase 1 active Biologic

At a glance

Generic name	EBV-specific T cells: B
Sponsor	Baylor College of Medicine
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EBV-specific T cells: B CI brief — competitive landscape report
EBV-specific T cells: B updates RSS · CI watch RSS
Baylor College of Medicine portfolio CI